Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G. Baumert, Roger Stupp, Thierry Gorlia et al.|The Lancet Oncology|2016Cited by 504
CTNI-14. RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDYBrigitta G. Baumert, Roger Stupp, Monika E. Hegi et al.|Neuro-Oncology|2024Cited by 4